This section has been archived. The COVID-19 Treatment Guidelines Panel will no longer be updating the information found here.
Table. Nitazoxanide: Selected Clinical Data
Last Updated: July 8, 2021
The information in this table may include data from preprints or articles that have not been peer reviewed. Please see ClinicalTrials.gov for more information on clinical trials that are evaluating NTZ for the treatment of COVID-19. The clinical trials described in this table do not represent all the trials that the Panel reviewed while developing recommendations for NTZ.1,2
Table. Nitazoxanide: Selected Clinical Data | |
|---|---|
References
- Blum VF, Cimerman S, Hunter JR, et al. Nitazoxanide superiority to placebo to treat moderate COVID-19–a pilot prove of concept randomized double-blind clinical trial. EClinicalMedicine. 2021. Available at: https://pubmed.ncbi.nlm.nih.gov/34222847/.
- Silva M, Espejo A, Pereyra ML, et al. Efficacy of nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study. medRxiv. 2021;Preprint. Available at: https://www.medrxiv.org/content/10.1101/2021.03.03.21252509v1.
- Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. Eur Respir J. 2021. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33361100.
- Rossignol J, Bardin MC, Oaks JB, et al. Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization. medRxiv. 2021;Preprint. Available at: https://www.medrxiv.org/content/10.1101/2021.04.19.21255441v1.